-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The NCI-COG Children's MATCH trial assigned patients aged 1-21 years with relapsed or refractory solid tumors, lymphomas , and histiocytic diseases into a phase II study for molecularly targeted therapy based on the detection of pre-defined genetic variants
Molecular targeting of childhood lymphoma
This article reports the outcomes of patients treated with selumetinib in this trial
Patients received selumetinib twice daily for 28 days until disease progression or unacceptable toxicity
The best remission status for 3 patients was stable disease
In conclusion, a national histology-unknown molecular screening strategy is effective in screening children and young adults for selumetinib therapy in the upcoming first pediatric MATCH treatment cohort
Screening for MEK inhibitors has shown promising efficacy in some pediatric tumors.
Original source:
Olive S.
leave a message here